Search Results - timothy collier

3 Results Sort By:

Nurr1 as a Genetic Target for Treating Levodopa-induced Dyskinesias (LIDs) in Parkinson's Disease

Executive SummaryPatients afflicted with Parkinson’s disease often develop severely debilitating movement disorders as side effects from currently available treatment options. Researchers at MSU propose to use a new gene therapy approach that will both reduce these side effects and prolong the effectiveness of treatment by targeted gene silencing.Description...
Published: 6/23/2016   |   Inventor(s): Fredric Manfredsson, Kathy Steece-Collier, Jack Lipton, Timothy Collier, Nicholas Kanaan, Caryl Sortwell
Keywords(s):   Category(s): Medical

Use of Sprr1 A-like Protein as a Neurorestorative and Neuroprotective Agent against Neurodegeneration in Parkinson's Disease

Executive SummaryAlthough the precise causes of Parkinson’s disease (PD) remain unclear, it has been long observed that those afflicted with the disease show widespread neurodegeneration of the central nervous system accompanied by a striking loss of dopamine producing neurons in the brain. Recent research suggests axonal degeneration of dopamine...
Published: 6/23/2016   |   Inventor(s): Nicholas Kanaan, Jack Lipton, Timothy Collier
Keywords(s):   Category(s): Medical

Genetic Targets and Gene Therapies for Treating Levodopa-induced Dyskinesias for Parkinsonisms

IntroductionThe Parkinson’s Disease Foundation estimates that there are 1.0 to 1.5 million people suffering from Parkinson’s disease (PD) in the United States alone. Those suffering from PD are afflicted with tremors in the limbs and face, rigidity and stiffness of the limbs and trunk, slowed movement, postural instability, and impaired...
Published: 4/9/2014   |   Inventor(s): Jack Lipton, Kathy Steece-Collier, Nicholas Kanaan, Timothy Collier, Fredric Manfredsson, Caryl Sortwell
Keywords(s):   Category(s): Medical, Pharmaceutical, Therapeutic